Pfizer’s Tofacitinib Clears FDA Without Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
With FDA’s early approval of tofacitinib for rheumatoid arthritis – the first JAK inhibitor and, unlike the popular TNF inhibitors, an oral agent – the agency appears to have sided with Pfizer on many issues left up in the air after an advisory committee review.